Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.
Hypothesis: Mexidol® allows to optimize POAG therapy by reducing mitochondrial dysfunction and stabilizing glaucomatous optic neuropathy by improving the functional activity of mitochondria and its energy-producing function
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
Neurocytoprotector
Tyumen Scientific Center of the Russian Academy of Sciences
Tyumen, Russian Federation, Russia
Degree of expression of mitochondrial dysfunction
Enzyme status of lymphocytes (Succinate dehydrogenase and Glycerophosphate dehydrogenase)
Time frame: 90 days
Dynamics of the structural and functional characteristics of mitochondria
Cytomorphodensitometry (number of mitochondria, their optical density, number of granules and deposits in the mitochondria of lymphocytes)
Time frame: 90 days
Аssessment of differential light sensitivity of the retina
Dynamics of index of mean deviation (MD) of retinal photosensitivity \[Static Automated Perimetry (SAP)\]
Time frame: 90 days
Structural and topographic changes in the layer of nerve fibers and the retinal ganglion [Optical Coherence Tomography (OCT) parameters]
The average thickness of retinal nerve fibers (RNFL) of the peripapillary zone in four quadrants was studied using the Fast RNFL Thickness program and the thickness of the retinal ganglion cell complex (GCC-Ganglion Cell Complex protocol)
Time frame: 90 days
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Adverse events related to Mexidol
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.